Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa

[at noodls] – 08 Feb 2013 San Diego, CA – February 8, 2013 – Shire plc (LSE: SHP, NASDAQ: SHPG), today announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute … more

View todays social media effects on SHPG

View the latest stocks trending across Twitter. Click to view dashboard

See who Shire is hiring next, click here to view